Sildenafil

Phase 2Withdrawn

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Persistent Pulmonary Hypertension of the Newborn

Conditions

Persistent Pulmonary Hypertension of the Newborn

Trial Timeline

Mar 1, 2012 → Apr 1, 2013

NCT ID

NCT01360671

About Sildenafil

Sildenafil is a phase 2 stage product being developed by Pfizer for Persistent Pulmonary Hypertension of the Newborn. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT01360671. Target conditions include Persistent Pulmonary Hypertension of the Newborn.

What happened to similar drugs?

4 of 8 similar drugs in Persistent Pulmonary Hypertension of the Newborn were approved

Approved (4) Terminated (1) Active (4)

✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved

✅RivastigmineNovartisApproved

✅Omalizumab + PlaceboNovartisApproved

✅irbesartan + placeboSanofiApproved

🔄E7777 9 mcg/kgEisaiPhase 3

🔄CertoparinNovartisPhase 3

🔄Omalizumab + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01897740	Pre-clinical	Completed	—	—	Pulmonary Arterial Hypertension
NCT01889966	Approved	Completed	Apr 1, 2013	Jan 1, 2015	Pulmonary Hypertension Associated With Connective Tissue Disease
NCT01642407	Approved	Completed	Aug 24, 2012	Mar 12, 2018	Pulmonary Arterial Hypertension
NCT01360671	Phase 2	Withdrawn	Mar 1, 2012	Apr 1, 2013	Persistent Pulmonary Hypertension of the Newborn
NCT01108900	Pre-clinical	Completed	Jul 1, 2010	Oct 1, 2011	Erectile Dysfunction
NCT00800592	Phase 1	Completed	Oct 1, 2008	Dec 1, 2008	Hypertension, Pulmonary
NCT00666198	Pre-clinical	Completed	May 1, 2008	Jun 1, 2015	Pulmonary Hypertension
NCT00768573	Pre-clinical	Completed	Jan 1, 2008	Jan 1, 2008	None Volunteer
NCT00625079	Approved	Withdrawn	Feb 1, 2007	Dec 1, 2009	Pulmonary Arterial Hypertension
NCT00249730	Approved	Completed	Oct 1, 2005	—	Impotence
NCT00245596	Approved	Completed	Oct 1, 2005	—	Impotence
NCT00746967	Phase 2	Completed	Jan 1, 2003	Feb 1, 2004	Sexual Dysfunctions, Psychological
NCT00145483	Approved	Completed	Jun 18, 2002	Nov 8, 2006	Meniere's Disease
NCT00375297	Approved	Completed	Jan 1, 2001	Jun 1, 2005	Sexual Dysfunction

Competing Products

20 competing products in Persistent Pulmonary Hypertension of the Newborn

See all competitors

Product	Company	Stage	Hype Score
E7777 9 mcg/kg	Eisai	Phase 3	40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
AZD0837 + VKA INR 2-3	AstraZeneca	Phase 2	35
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate	Novartis	Phase 2	35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo	Novartis	Approved	35
Certoparin	Novartis	Phase 3	40
Omalizumab + Placebo	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days	Novartis	Phase 2	35
Indacaterol + Placebo to Indacaterol	Novartis	Phase 2	35
Omalizumab + Placebo	Novartis	Approved	43
placebo + iv sildenafil	Pfizer	Phase 3	40
etanercept + placebo	Pfizer	Phase 2	35
irbesartan + placebo	Sanofi	Approved	39
iloprost	Bayer	Pre-clinical	15
IV Remodulin + Placebo	United Therapeutics	Phase 2	24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	24